Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 121,061

Document Document Title
WO2017008686A1
Provided is an adipose-derived stem cell in which a thromboxane A2 receptor (TP) is deactivated or inhibited and/or the activity of a calpain is deactivated or reduced, and/or the activity of a β-catenin is enhanced. Also provided are a...  
WO2016170124A3
The present invention relates to the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.  
WO2016016380A8
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharma...  
WO2017009750A1
Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.  
WO2017009454A1
The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission ...  
WO2017008737A1
Disclosed is a natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof. The formulation of the composition consists in mass percentage of 70%-97.5% sea buckthorn fruit oil and ...  
WO2017008205A1
Provide the compound of generic formula I: The compound can be useful as A2A-receptor antagonist. Use the compound for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the recepto...  
WO2017010520A1
A composition for protecting optic nerve cells, for preventing or treating glaucoma, for suppressing retinal ganglionic cell death, or slowing the progression of vision loss in humans containing at least one selected from the group consi...  
WO/2017/009274A1
The present invention relates to compounds of formula (I) wherein R1' is CH3; R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1 -dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO2016199170A3
The present invention disclosed relates to Paliperidone palmitate particles, a process to manufacture the same and pharmaceutical compositions thereof. It further relates to the use of such pharmaceutical compositions in the treatment of...  
WO2017011556A1
The disclosure provides novel forms of phosphorylated tau species and applications thereof, as well as methods of diagnosing and/or treating tau-associated neurodegeneration.  
WO/2017/009308A3
The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and...  
WO2017009275A1
The present invention relates to compounds of formula I wherein R1 is lower alkyl; R2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other ...  
WO/2017/009312A1
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse L...  
WO2017009472A1
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...  
WO2017010537A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for said composition in order to inhibit carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery o...  
WO2017008638A1
Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A beta 1-m peptide (m being an integer between 6 and 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also ...  
WO/2017/010133A1
Provided are a carnosine dipeptidase 1 inhibitor composition, a use for a material that inhibits carnosine dipeptidase 1, and a method for inhibiting carnosine dipeptidase 1. The present invention demonstrates the discovery of a plant- o...  
WO2017011352A1
Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-βΙ. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need t...  
WO2017010414A1
The invention addresses the problem of providing a cell construct of at least a predetermined size that can be produced in a short period of time, and a method for producing the cell construct. The invention provides a cell construct inc...  
WO2016160574A3
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2017/007938A1
Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B rece...  
WO/2017/004966A1
The present invention relates to a new pyrazine derivative, and preparation method and medical application thereof. The pyrazine derivative can remove a free radical, suppress calcium overload, has an effect of protecting cells, and is u...  
WO/2017/007813A1
Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase...  
WO/2017/007960A1
The present disclosure provides compositions, kits, and methods of promoting neural growth and/or neural survival using IL-17c. The compositions, kits, and methods can be used to promote neural growth and/or neural survival in a variety ...  
WO/2017/007825A1
In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective...  
WO/2017/006932A1
The present invention relates to a composition for treating peripheral nerve injury, which can promote normal regeneration of nerves when the nerves are injured and consequently can prevent the formation of neuroma to prevent the subsequ...  
WO/2017/005136A1
Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors ...  
WO/2017/006048A1
The invention relates to compounds of formula I (I) or the salts thereof, and to the use of same in the pharmaceutical, cosmetic or agrofood industry.  
WO/2017/005711A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting phosphorous- and sulfur-substituted benzodiazepine derivatives of the general formula (I), in which R1, R2, R3,...  
WO/2017/007755A1
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a sub...  
WO/2017/007008A1
Provided are novel low-molecular-weight compounds for suppressing the inductive production of MMPs, especially MMP-9, rather than the constitutive production of MMP-2. The present invention pertains to compounds represented by formula (I...  
WO/2017/006953A1
Provided is a compound having TrkA-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceu...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2017/006290A1
The present application relates to a modified release composition comprising nicergoline, or its pharmaceutically acceptable salt thereof, at least one rate-controlling polymer and one or more other pharmaceutically acceptable excipients...  
WO/2017/006407A1
A nerve cell death inhibitor, an anti-Alzheimer's disease agent, a brain hypofunction inhibitor and a drug or food having an anti-Alzheimer's disease effect or a brain hypofunction-inhibiting effect, each containing as an active ingredie...  
WO/2017/003466A1
The subject invention concerns materials and methods for conversion of non- neuronal cells into neurons. The subject invention also concerns methods for screening drugs and other compounds for activity in treating Alzheimer's disease usi...  
WO/2017/000276A1
The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). ...  
WO/2017/001570A3
Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the org...  
WO/2017/000869A1
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...  
WO/2017/004385A1
A method for detecting circulating levels of beta amyloid peptides in an individual by administration of one or more inhibitors of an extracellular proteolytic pathway in blood and detection of the beta amyloid peptides in the blood or a...  
WO/2017/004405A1
Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated...  
WO/2017/003935A1
TThe present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depr...  
WO/2017/002829A1
[Problem] To prevent abuse of a pharmacologically active ingredient by an abuser by providing a pharmaceutical composition having an abuse-prevention function (abuse by nasal inhalation, abuse by injection, and abuse by extracting a drug...  
WO/2017/000270A1
The present invention relates to a crystal form A and a crystal form B of sertraline citrate, and preparation methods therefor. The crystal form A and the crystal form B of sertraline citrate have good dissolvability, high dissolution an...  
WO/2017/000277A1
The present invention is directed to substituted triazolo bicycliccompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The prese...  
WO/2017/001568A1
The invention relates to the use of interleukin 4 for preventing and treating amyotrophic lateral sclerosis. In particular, the invention relates to the use of an interleukin 4 polypeptide, a nucleic acid encoding said polypeptide or a c...  
WO/2017/004408A1
Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the sma...  
WO/2017/004226A1
The present disclosure relates to the use of inositol-stabilized arginine ("ASI") for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Som...  
WO/2017/003995A1
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.  

Matches 301 - 350 out of 121,061